Online citations, reference lists, and bibliographies.
← Back to Search

Mammaglobin Expression In Leukapheresis Products Is A Predictive Marker Of Poor Prognosis In Women With High-risk Breast Cancer.

P. Ferrucci, C. Rabascio, C. Mazzetta, E. Cocorocchio, A. Agazzi, A. Vanazzi, S. Cinieri, F. Peccatori, M. Paolucci, F. Bertolini, G. Martinelli
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE The purpose of this study was to investigate the incidence and prognostic relevance of tumor cell detection in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections (PBPCCs) using cytokeratin (CK), maspin (MAS), and mammaglobin (MAM) genes as epithelial cell markers. The population on which the study was conducted was drawn from stage III breast cancer patients undergoing high-dose chemotherapy and autologous transplantation with PBPCCs. EXPERIMENTAL DESIGN One hundred and ninety-four patients were enrolled in the study and analyzed for tumor cell detection on the basis of 481 PBPCCs gathered before administration of chemotherapy. CK, MAS, and MAM gene expressions were investigated by means of the reverse transcription nested polymerase chain reaction, and those samples expressing CK were further hybridized with a radiolabeled internal probe to reduce false-positive results. Sensitivity and specificity were assessed on 37 controls (12 cell lines, 12 healthy donors, and 13 nonepithelial malignancies). Each of the known prognostic variables (age, stage, lymph node status, receptor status, c-ErbB2 status, and Ki67 status) was then analyzed (both individually and together with CK, MAS, and MAM expression on PBPCCs) in relation to patient overall survival (OS) and relapse-free survival (RFS). RESULTS After a 3-year follow-up, an estimated 83% (95% confidence interval, 77.1-88.8%) of the patients were alive and an estimated 67% (95% confidence interval, 60.1-74.6%) were free of relapse. One hundred and seventy-six of the 194 patients (91%) had contaminated PBPCCs evidenced by at least one positive sample for any of the markers evaluated. The PBPCC frequency of CK, MAS, and MAM positivity (+) was 71%, 36%, and 16%, respectively. MAM expression on PBPCC was associated with an increased risk of relapse (P = 0.003), whereas CK and MAS expressions were not associated with changes in either RFS or OS. CONCLUSIONS MAM gene expression on leukapheresis products of high-risk breast cancer patients is an indicator of poor prognosis. The method of evaluation is simple and reproducible and provides new tools for evaluating the role played by tumor cells in apheresis products and their potential in causing metastasis.
This paper references
10.1093/jnci/90.14.1099
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
I. Diel (1996)
10.1200/JCO.1991.9.10.1749
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.
R. Cote (1991)
10.1200/JCO.1996.14.6.1868
Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.
K. Fields (1996)
10.1038/sj.bmt.1703929
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy
F. Patriarca (2003)
10.1038/sj.bmt.1704133
Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT)
R. Syme (2003)
10.1056/NEJM200002243420801
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
S. Braun (2000)
10.1159/000046560
Detection of Epithelial Cells in Hematopoietic Organs of Patients with Breast Cancer
C. Chabannon (2001)
Mammaglobin expression in primary, metastatic, and occult breast cancer.
M. Watson (1999)
10.1200/JCO.1998.16.2.557
Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.
I. Funke (1998)
10.1093/ANNONC/MDF107
Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products.
A. L. Silva (2002)
10.1046/j.1365-2559.2003.01620.x
Expression of maspin is up‐regulated during the progression of mammary ductal carcinoma
Y. Umekita (2003)
10.1002/path.1319
Maspin expression in invasive breast cancer: association with other prognostic factors
S. Mohsin (2003)
10.1093/OXFORDJOURNALS.ANNONC.A010680
Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene.
M. Luppi (1996)
10.1111/j.1749-6632.1994.tb21713.x
Gene Marking and Autologous Bone Marrow Transplantation a
M. Brenner (1994)
10.1200/JCO.1989.7.4.445
The fate of bone marrow micrometastases in patients with primary breast cancer.
J. Mansi (1989)
10.3816/CBC.2002.N.032
Expression and regulation of tumor suppressor gene maspin in breast cancer.
N. Maass (2002)
10.1182/BLOOD.V94.1.340.413K09_340_347
Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone.
W. Franklin (1999)
10.1126/SCIENCE.8290962
Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.
Z. Zou (1994)
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
S. Kasimir-Bauer (2001)
10.1097/00019606-199609000-00005
High‐sensitivity Detection of Minimal Residual Breast Carcinoma Using the Polymerase Chain Reaction and Primers for Cytokeratin 19
L. Moscinski (1996)
( ABSCT )
S Kasimir-Bauer (2003)
Prognostic and therapeutic significance of pathological features of breast cancer.
E. Fisher (1986)
10.1182/blood.v83.3.636.636
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.
W. Brugger (1994)
10.1038/72303
Maspin is an angiogenesis inhibitor
M. Zhang (2000)
Detection and clinical significance of minimal TCC of peripheral blood stem cells harvests [abstract 92
JC Sharp (1992)
10.1111/j.1349-7006.2003.tb01359.x
Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients
Y. Lin (2003)
10.1200/JCO.1999.17.7.2015
Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA.
O. Zach (1999)
Expression of the maspin gene, a recently discovered antiangiogenesis tumor suppressor, protects high risk breast cancer patients from relapse
PF Ferrucci (2000)
10.1016/S1043-321X(99)92039-8
Tamoxifen for early breast cancer: An overview of the randomised trials
D. Tripathy (1999)
Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer.
M. Watson (1996)
10.1016/S0361-090X(02)00009-0
Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene.
P. Bossolasco (2002)
Prognostic value of maspin mRNA expression in ER alphapositive postmenopausal breast carcino
PF Ferrucci (2003)
10.1038/sj.bmt.1702815
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction
F. Leone (2001)
10.1038/sj.bjc.6600812
Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas
I. Bieche (2003)
10.1182/BLOOD.V82.9.2605.BLOODJOURNAL8292605
Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques.
A. Ross (1993)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar